Sagent Pharma Reports Reintroduction of Amiodarone HCL Injection

Sagent Pharmaceuticals, Inc. SGNT today announced the reintroduction of Amiodarone HCl Injection, an antiarrhythmic agent, now in an improved prefilled plastic syringe that is compatible with most standard I.V. pumps. According to IMS, for the 12 months ending June 2013, the US market for Amiodarone HCl Injection approximated $16 million. As with all products in Sagent's portfolio, Amiodarone features Sagent's PreventIV Measures^SM packaging and labeling, designed to help reduce medication errors.